Company intelligence / Profile preview

Faulk Pharmaceuticals

La Jolla, California, United States

Ownership: Private
Development stage: Other

Overview

Faulk Pharmaceuticals developed a ligand-drug conjugate platform with lead asset TRF-DOX showing improved survival in ovarian cancer and responses in leukemia and angiosarcoma in early studies. Assets acquired by Panther Biotechnology in 2015; no recent clinical advancement reported.[2]

Therapeutic areas: Oncology
Modalities: Ligand-drug conjugate
Industry: Biotech

Beyond the preview

Go deeper on Faulk Pharmaceuticals.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Faulk Pharmaceuticals.

Explore the full profile